表紙:外陰膣カンジダ症向け医薬品の世界市場:2020~2027年
市場調査レポート
商品コード
987852

外陰膣カンジダ症向け医薬品の世界市場:2020~2027年

Global Drugs for Vulvovaginal Candidiasis Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.56円
外陰膣カンジダ症向け医薬品の世界市場:2020~2027年
出版日: 2021年02月09日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界における外陰膣カンジダ症向け医薬品市場の成長をリードする要因には、カンジダ症の有病率の上昇、研究開発費の増加、および新興市場における未開拓の機会が含まれます。ただし、発展途上経済諸国における外陰膣カンジダ症に関する認識の不足は、予測期間中の市場成長を妨げる見込みです。

当レポートでは、世界の外陰膣カンジダ症向け医薬品市場について調査分析し、市場の概要、市場成長への影響要因、各セグメント・地域別による市場規模と前年比成長、および主要企業などについて分析しています。

目次

第1章 世界の外陰膣カンジダ症向け医薬品市場:調査手法・範囲

  • 調査手法
  • 調査目的・範囲

第2章 世界の外陰膣カンジダ症向け医薬品市場:市場の定義・概要

第3章 世界の外陰膣カンジダ症向け医薬品市場:エグゼクティブサマリー

  • 市場内訳:製剤タイプ別
  • 市場内訳:薬剤タイプ別
  • 市場内訳:エンドユーザー別
  • 市場内訳:地域別

第4章 世界の外陰膣カンジダ症向け医薬品市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の外陰膣カンジダ症向け医薬品市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 世界の外陰膣カンジダ症向け医薬品市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以降または将来のシナリオ
  • Covid-19期間中の価格ダイナミクス
  • 需要と供給のスペクトル
  • パンデミック期間中の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ

第7章 世界の外陰膣カンジダ症向け医薬品市場:製剤タイプ別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):製剤タイプ別
  • 市場魅力指数:製剤タイプ別
    • 局所
    • ペッサリー
    • 経口

第8章 世界の外陰膣カンジダ症向け医薬品市場:薬剤タイプ別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):薬剤タイプ別
  • 市場魅力指数:薬剤タイプ別
    • ミコナゾール
    • クロトリマゾール
    • フルコナゾール
    • エコナゾール

第9章 世界の外陰膣カンジダ症向け医薬品市場:エンドユーザー別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):エンドユーザー別
  • 市場魅力指数:エンドユーザー別
    • 病院&クリニック
    • 薬局

第10章 世界の外陰膣カンジダ症向け医薬品市場:地域別

  • イントロダクション
    • 市場規模分析および前年比成長分析(%):地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析および前年比成長分析(%):製剤タイプ別
    • 市場規模分析および前年比成長分析(%):薬剤タイプ別
    • 市場規模分析および前年比成長分析(%):エンドユーザー別
    • 市場規模分析および前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の外陰膣カンジダ症向け医薬品市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 企業プロファイル

  • Actavis PLC
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主なハイライト
    • 財務概要
  • Cisen Pharmaceutical
  • Bayer AG
  • Bristol-Myers Squibb
  • Effik SA
  • Kingyork Group
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Mycovia Pharmaceuticals

第13章 世界の外陰膣カンジダ症向け医薬品市場:重要考察

第14章 世界の外陰膣カンジダ症向け医薬品市場:DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次

Market Overview

Candidiasis is an infection caused by a yeast called Candida fungi, among which, the most common is Candida albicans. This fungi normally lives on the skin as well as inside the body, in places such as the throat, gut, mouth, and vagina, without causing any problems. The Candida fungi can cause infections, incase if it grows out of control or if enters into the body, such as the bloodstream or internal organs, including the kidney, brain, or heart. However, the candida infections are hardly ever serious in healthy people. In a fewer cases, it may even spread through other parts of the body if the patient's immune system is not working properly.

The global drugs for vulvovaginal candidiasis market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Certain factors that are leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding the vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.

Expecetd increase in the prevalence of candidiasis

Candidemia is one of the commonly bloodstream infections in the US. The average incidence was around 9 per 100,000 people, as per the Centers for Disease Control and Prevention (CDC). The organization has further estimated that around 25,000 cases of candidemia occur in the US each year. However, as per CDC, the incidence of candidemia declined in among infants and elderly people in the US during 2009 to 2012. This decline was due to the changes in prophylaxis guidelines and enhanced infection control practices, such as catheter care and hand hygiene. Though, the incidence of candidemia is expected to slightly increase during the forecast period, backed by the rise in the awareness of symptoms associated with candidemia.

Increasing R&D expenditure and expansion of product pipeline

The market for the fungal disease treatment has led to the introduction of a number of effective and safe antifungal agents. A few of the most effective therapies available in the market includes itraconazole, terbinafine, and fluconazole. The increasing R&D spending by the pharmaceutical companies for the development of advanced product pipeline for anti-infective drugs is one of the major factors augmenting the growth of the antifungal drug industry, which in turn, is expected to escalate the drugs for vulvovaginal candidiasis market. The market players are focusing on the development of effective therapeutic agents in immunocompromised patients to cure systemic fungal infections, including candidemia.

COVID-19 Impact Analysis

A increase in the market value of drugs for vulvovaginal candidiasis is expected in 2020, backed by the rise in the prevalence of invasive candidiasis in patients dealing with COVID-19. This is due to the rise in the healthcare-associated infections (HIAs), including cloodstream infections such as candidiasis, especially in patinets that are admitted to hospitals. Therefore, the demand for drugs for vulvovaginal candidiasis increased amid the COVID-19 pandemic, which in turn, increased the sales of the drug in 2020.

Segment Analysis

Based on the drug type, the drugs for vulvovaginal candidiasis market has been classified into miconazole, clotrimazole, fluconazole, and econazole.

Miconazole segment contributed significant share to the global drugs for vulvovaginal candidiasis market in 2019

Miconazole is a synthetic imidazole antifungal drug that eases the symptoms of candidasis by killing the candida fungus. It is majorly used as an effective treatment for vaginal thrush and fungal infections in other parts of the body. It is an oral gel that is available in the market on a prescription from a doctor; however, it can also be bought in smaller packs from pharmacies, without a prescription. It acts rapidly in relieving symptoms of yeasts, dermatophytes, and gram-positive bacteria, available for topical therapy of skin infections.

Based on the formulation type, the drugs for vulvovaginal candidiasis market has been classified into topical, pecessary, and oral.

Topical lead the market throughout the forecast period

Topical segment led the overall market with a share in 2019. A topical formulation of drugs for vulvovaginal candidiasis is used for the treatment of diseases related to the vaginal yeast, which reduces vaginal itching, pain, and discharge with this condition. The topical drug is an antifungal azole, which functions by preventing the growth of the infection-causing yeast.

Geographical Analysis

Based on geography, the study analyzes the drugs for vulvovaginal candidiasis market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominated the global drugs for vulvovaginal candidiasis market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American drugs for vulvovaginal candidiasis market in 2019. The high awareness regarding the vaginal infection from candida is one of the major factor propelling the growth of the market in the region. Moreover, the key market players are headquartered in the US, such as Pfizer Inc. and Johnson & Johnson Services Inc. are further escalating the growth of the market in North America.

Moreover, Asia Pacific is expected to project the fastest growth rate in the drugs for vulvovaginal candidiasis market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific drugs for vulvovaginal candidiasis market during the forecast period. The expansion of global market players in the Asia-Pacific region due to the rising prevalence of vulvovaginal candidiasis in the region are certain factors that will propel the market growth during the forecast period.

Competitive Landscape

The drugs for vulvovaginal candidiasis market is highly competitive, owing to the large presence of drugs for vulvovaginal candidiasis brands. The key drugs for vulvovaginal candidiasis players include Actavis PLC, Bristol-Myers Squibb, Bayer AG, Effik SA, Cisen Pharmaceutical, Sanofi SA, Kingyork Group, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Services Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the drugs for vulvovaginal candidiasis market.

Pfizer Inc.

Overview: Pfizer Inc. is a research-based pharmaceutical company that is engaged in the discovery, development, and marketing of healthcare products, including vaccines and medicines. The company operates its business across two segments, namely Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). The company develops and provides over 170 different vaccines and medicines to the global market.

Product Portfolio: The company's portfolio comprises fluconazole.

Why Purchase the Report?

  • Visualize the drugs for vulvovaginal candidiasis market segmentation composition by formulation type, drug type, end user, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the drugs for vulvovaginal candidiasis market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of drugs for vulvovaginal candidiasis market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global drugs for vulvovaginal candidiasis market report would provide access to an approx. 57 market data tables, 54 figures, and 262 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Drugs for Vulvovaginal Candidiasis Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Drugs for Vulvovaginal Candidiasis Market - Market Definition and Overview

3. Global Drugs for Vulvovaginal Candidiasis Market - Executive Summary

  • 3.1. Market Snippet by Formulation Type
  • 3.2. Market Snippet by Drug Type
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Drugs for Vulvovaginal Candidiasis Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Candidiasis
      • 4.1.1.2. Rise in R&D spending
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness regarding vulvovaginal candidiasis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Drugs for Vulvovaginal Candidiasis Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Drugs for Vulvovaginal Candidiasis Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Drugs for Vulvovaginal Candidiasis Market - By Formulation Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type Segment
  • 7.3. Market Attractiveness Index, By Formulation Type Segment
    • 7.3.1. Topical*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Pessary
    • 7.3.3. Oral

8. Global Drugs for Vulvovaginal Candidiasis Market - By Drug Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 8.3. Market Attractiveness Index, By Drug Type Segment
    • 8.3.1. Miconazole*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Clotrimazole
    • 8.3.3. Fluconazole
    • 8.3.4. Econazole

9. Global Drugs for Vulvovaginal Candidiasis Market - By End User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 9.3. Market Attractiveness Index, By End User Segment
    • 9.3.1. Hospital & Clinics*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Pharmacy

10. Global Drugs for Vulvovaginal Candidiasis Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Drugs for Vulvovaginal Candidiasis Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Drugs for Vulvovaginal Candidiasis Market- Company Profiles

  • 12.1. Actavis PLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cisen Pharmaceutical
  • 12.3. Bayer AG
  • 12.4. Bristol-Myers Squibb
  • 12.5. Effik SA
  • 12.6. Kingyork Group
  • 12.7. Sanofi SA
  • 12.8. Teva Pharmaceutical Industries Ltd.
  • 12.9. Johnson & Johnson Services Inc.
  • 12.10. Pfizer Inc.
  • 12.11. Mycovia Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Global Drugs for Vulvovaginal Candidiasis Market - Premium Insights

14. Global Drugs for Vulvovaginal Candidiasis Market - DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us